WO2017086692A1 - Composition de blanchiment de la peau utilisant un extrait de dipterocarpus intricatus - Google Patents

Composition de blanchiment de la peau utilisant un extrait de dipterocarpus intricatus Download PDF

Info

Publication number
WO2017086692A1
WO2017086692A1 PCT/KR2016/013203 KR2016013203W WO2017086692A1 WO 2017086692 A1 WO2017086692 A1 WO 2017086692A1 KR 2016013203 W KR2016013203 W KR 2016013203W WO 2017086692 A1 WO2017086692 A1 WO 2017086692A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
composition
skin whitening
intricatus
present
Prior art date
Application number
PCT/KR2016/013203
Other languages
English (en)
Korean (ko)
Inventor
강재신
변혜우
오경희
이재호
챙킴선
크라이마스팔
오좌섭
안은경
박영진
Original Assignee
대한민국(환경부 국립생물자원관장)
재단법인 경기과학기술진흥원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 대한민국(환경부 국립생물자원관장), 재단법인 경기과학기술진흥원 filed Critical 대한민국(환경부 국립생물자원관장)
Publication of WO2017086692A1 publication Critical patent/WO2017086692A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Definitions

  • Dipterocarpus Intricatus ( Dipterocarpus) Intricatus ) relates to a skin whitening composition using the extract.
  • Human skin color depends on a number of factors, in particular by season, race and sex, and is mainly determined by the amount of melanin, carotene and hemoglobin, of which melanin is the most decisive factor.
  • Melanin is a phenolic polymer natural pigment widely present in living organisms.
  • melanin is synthesized in melanosomes in melanocytes in the basal epidermal layer and transferred to surrounding keratinocytes to represent human skin color.
  • Abnormally low melanin causes skin lesions, such as vitiligo, and conversely, when overproduced, acquired hyperpigmentation such as melasma, postinflammatory melanoderma, and solar lentigo It can cause a variety of skin diseases, including.
  • tyrosine is synthesized by the continuous oxidation of tyrosine, which is a substrate. Specifically, tyrosine is synthesized from tyrosinase, tyrosinase related protein-1 (TRP-1) and tyrosinase related protein-2 (TRP-2). It is converted into dopa quinone via dopa (DOPA, 3,4-dihydroxyphenylalanine) by action, and then synthesized by polymerization reaction with amino acid or protein through non-enzymatic reaction and spontaneous oxidation process.
  • DOPA dopa quinone
  • FOOD SCI. TECHNOL. 32 (3): 736, 2000; Journal of Life Science, 23 (12): 1445, 2013).
  • tyrosinase plays the most important role as the first step in producing melanin
  • the search for various tyrosinase inhibitors has been ongoing for the development of whitening agents (Kor. J. Pharmacogn., 44 (3): 220
  • melanin synthesis targeting signal transduction agents such as microphtalmia associated transcription factor (MITF)
  • the major intracellular signaling pathway is the cAMP / PKA pathway (cyclic monophosphate / protein kinase A pathway).
  • CAMP promotes the expression of the transcriptional regulator MITF via PKA and CREB1 (cAMP responsive element binding protein 1).
  • Arbutin the most widely used whitening agent, is an inhibitor that works competitively with L-tyrosine, and kojic acid chelates the tyrosinase active site to dopa and dopaquinone in tyrosine.
  • Arbutin and kojic acid are known to have a strong whitening effect, but due to some side effects such as skin irritation, research has been actively conducted to find a material having a whitening activity from a relatively low side effects of natural substances.
  • the present invention discloses Diphterocapus intricatus extract having tyrosinase inhibitory activity and melanin production inhibitory activity.
  • diphtherocapus intricatus extract is treated with B16F10 which is a melanoma cell stimulated with ⁇ -MSH, which exhibits high tyrosinase inhibitory activity and is a melanogenesis-stimulating agent.
  • B16F10 which is a melanoma cell stimulated with ⁇ -MSH, which exhibits high tyrosinase inhibitory activity and is a melanogenesis-stimulating agent.
  • concentration-dependent melanin production inhibitory activity, and further, the tyrosinase inhibitory activity and melanin production inhibitory activity is completed by confirming that it is comparable to or superior to arbutin synthetic synthetic synthetic whitening agent.
  • Diphterocarpus Intricatus is a plant belonging to the family Dipterocarpaceae, native to Thailand, Cambodia, Laos and Vietnam.
  • the skin whitening composition of the present invention is characterized in that it contains Diphterocappus intricatus extract as an active ingredient.
  • diphterocapus intricatus extract refers to diphterocapus intricatus stem, leaves, berries, flowers, roots, etc., which are extracted, lower alcohols having 1 to 4 carbon atoms such as water, methanol, ethanol, butanol, Methylene chloride, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol or theirs
  • An extract obtained by leaching using a mixed solvent an extract obtained by using a supercritical extraction solvent such as carbon dioxide or pentane, or a fraction obtained by fractionating the extract.
  • the extraction method takes into account the polarity, the degree of extraction, and the degree of preservation of the active substance. And any method such as cooling, refluxing, heating, ultrasonic radiation, and supercritical extraction can be applied.
  • the fractionated extract the fraction obtained by suspending the extract in a specific solvent and mixing and standing with a solvent having a different polarity, adsorbing the extract on a column filled with silica gel or the like, and then using a hydrophobic solvent, a hydrophilic solvent, or a mixed solvent thereof It is meant to include fractions obtained by mobile phase.
  • the meaning of the extract includes a concentrated liquid extract or solid extract in which the extraction solvent is removed in a manner such as freeze drying, vacuum drying, hot air drying, spray drying, and the like.
  • it refers to an extract obtained by using water, ethanol or a mixed solvent thereof as the extraction solvent, more preferably an extract obtained by using a mixed solvent of water and ethanol as the extraction solvent.
  • the "active ingredient” means a component that can exhibit the desired activity alone or in combination with a carrier which is itself inactive.
  • skin whitening may be understood as an increase in skin brightness reduced due to excessive production of melanin, specifically, improvement (reduction of symptoms) such as blemishes, freckles, and mushrooms caused by excessive production of melanin, By treatment, prevention, expression inhibition or delay.
  • the skin whitening composition of the present invention may further include any compound or plant extract that has already been tested for safety and known to have skin whitening activity in order to enhance and enhance the skin whitening effect.
  • compounds or extracts include arbutin, niacinamide, ascorbyl glucoside, alpha-bisabolol, oil-soluble licorice extract (Oil Soluble Licorice (Glycyrrhiza) Extract), and the like. You can refer to the functional cosmetics regulations according to the "Functional Cosmetic Standards and Test Methods".
  • Such compounds or plant extracts may be included in the composition for skin whitening of the present invention with one or more active ingredients thereof.
  • the active ingredient may be included in any amount within a range that does not toxic to the human body depending on the use, formulation, etc., specifically, 0.01 to 99.99% by weight relative to the total weight of the composition It may be included in weight percent.
  • the skin whitening composition of this invention can be grasped
  • the cosmetic composition of the present invention may include, in addition to the active ingredient, components conventionally used in the cosmetic composition, for example, conventional adjuvants such as stabilizers, solubilizers, surfactants, vitamins, pigments and pharmaceuticals, and carriers.
  • conventional adjuvants such as stabilizers, solubilizers, surfactants, vitamins, pigments and pharmaceuticals, and carriers.
  • Cosmetic compositions of the present invention may be prepared in any formulation conventionally prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing , Oils, powder foundations, emulsion foundations, wax foundations, sprays and the like.
  • it may be prepared in the form of a flexible lotion, a nourishing lotion, a nourishing cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.
  • the formulation of the present invention is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components.
  • animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components.
  • animal oils vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide
  • cellulose derivatives polyethylene glycols
  • silicones bentonites
  • silicas talc or zinc oxide
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
  • a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 , 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol, fatty acid ester of sorbitan and the like can be used.
  • a liquid diluent such as water, ethanol or propylene glycol
  • a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, polyoxyethylene sorbitan ester, and microcrystals
  • carrier components such as water, ethanol or propylene glycol
  • ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, polyoxyethylene sorbitan ester, and microcrystals are used as carrier components.
  • Castle cellulose, aluminum metahydroxy, bentonite, agar and the like can be used.
  • the carrier component is aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide.
  • Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
  • the cosmetic composition of the present invention may be prepared to include skin wrinkle improvement ingredients, UV protection ingredients and the like known in the art to enhance and add skin-related activities. Specific examples of such ingredients may be referred to the functional cosmetics code according to the cosmetic method.
  • the cosmetic composition of the present invention can be prepared according to the manufacturing method of the cosmetic composition usually carried out in the art, except for including the active ingredient exhibiting skin whitening activity.
  • the skin whitening composition of this invention can be grasped
  • the food composition of the present invention can be prepared as a health functional food, such as functional beverages, health supplements, foods for special nutrition supplements, the form of the food, beverages such as tea, juice, carbonated beverages, ionic beverages, milk, yogurt, etc.
  • Health functional food preparations such as processed oils, gums, rice cakes, Korean foods, breads, sweets, cotton, tablets, capsules, pills, granules, liquids, powders, flakes, pastes, syrups, gels, jelly, bars And the like.
  • the food composition of the present invention may include sweeteners, flavoring agents, bioactive ingredients, minerals, etc. in addition to the active ingredients.
  • Sweeteners may be used in amounts that give the food a suitable sweet taste, and may be natural or synthetic.
  • a natural sweetener is used.
  • sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose and maltose.
  • Flavoring agents can be used to enhance the taste or aroma, both natural and synthetic. It is the case of using a natural thing preferably.
  • the natural flavor may be obtained from apples, lemons, citrus fruits, grapes, strawberries, peaches, and the like, or may be obtained from green tea leaves, round leaves, jujube leaves, cinnamon, chrysanthemum leaves, jasmine and the like.
  • ginseng red ginseng
  • bamboo shoots aloe vera, ginkgo and the like can also be used.
  • Natural flavors can be liquid concentrates or solid extracts.
  • synthetic flavoring agents may be used, and synthetic flavoring agents may include esters, alcohols, aldehydes, terpenes, and the like.
  • catechins such as catechin, epicatechin, gallocatechin, epigallocatechin, vitamins such as retinol, ascorbic acid, tocopherol, calciferol, thiamine, riboflavin, and the like can be used.
  • mineral calcium, magnesium, chromium, cobalt, copper, fluoride, germanium, iodine, iron, lithium, magnesium, manganese, molybdenum, phosphorus, potassium, selenium, silicon, sodium, sulfur, vanadium, zinc and the like can be used.
  • the food composition of the present invention may contain a preservative, an emulsifier, an acidulant, a thickener, and the like, in addition to the sweetener.
  • Such preservatives, emulsifiers and the like are preferably added and used in trace amounts as long as the use to which they are added can be achieved.
  • trace numerically means 0.005% to about 0.5% by weight, based on the total weight of the food composition.
  • Preservatives that can be used include calcium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, EDTA (ethylenediaminetetraacetic acid), and the like.
  • Emulsifiers that can be used include acacia gum, carboxymethylcellulose, xanthan gum, pectin and the like.
  • acidulants examples include lead acid, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, phosphoric acid, and the like. Such acidulant may be added so that the food composition is at an appropriate acidity for the purpose of inhibiting the growth of microorganisms in addition to the purpose of enhancing taste.
  • Thickeners that can be used include suspending implements, sedimenters, gel formers, swelling agents and the like.
  • composition for skin whitening of the present invention can be regarded as a pharmaceutical composition in specific embodiments.
  • the target disease may be understood as skin hyperpigmentation, and specific examples of such hyperpigmentation include freckles, senile spots, liver spots, blemishes, brown or sunspots, and sun pigments.
  • skin hyperpigmentation include freckles, senile spots, liver spots, blemishes, brown or sunspots, and sun pigments.
  • compositions of the present invention may be prepared in oral or parenteral formulations according to the route of administration by conventional methods known in the art, including pharmaceutically acceptable carriers in addition to the active ingredient.
  • pharmaceutically acceptable here means that the subject of application (prescription) is not toxic as far as adaptable without inhibiting the activity of the active ingredient.
  • composition of the present invention is prepared in an oral dosage form, powders, granules, tablets, pills, dragees, capsules, solutions, gels, syrups, suspensions, wafers according to methods known in the art with suitable carriers It may be prepared in a formulation such as.
  • suitable pharmaceutically acceptable carriers include lactose, glucose, sucrose, dextrose, sugars such as sorbitol, mannitol, xylitol, starch such as corn starch, potato starch, wheat starch, cellulose, methylcellulose, ethylcellulose, Celluloses such as sodium carboxymethylcellulose, hydroxypropylmethylcellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate, mineral oil, malt, gelatin, talc, polyol, vegetable Yu etc. can be mentioned. If formulated, it may be formulated to include diluents and / or excipients, such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, if necessary.
  • diluents and / or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, if necessary.
  • compositions of the present invention When the pharmaceutical compositions of the present invention are prepared in parenteral formulations, they may be formulated in the form of injections, transdermal administrations, nasal inhalants and suppositories with suitable carriers according to methods known in the art.
  • suitable carriers include sterile water, ethanol, polyols such as glycerol or propylene glycol, or mixtures thereof.
  • PBS phosphate buffered saline
  • Ringer's solution or triethanol amine or sterile water for injection Isotonic solutions such as 5% dextrose, and the like can be used.
  • transdermal administration When formulated as a transdermal administration, it may be formulated in the form of an ointment, cream, lotion, gel, external solution, pasta, linen, aerosol and the like.
  • Nasal inhalants can be formulated in the form of aerosol sprays using suitable propellants such as dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, etc.
  • suitable propellants such as dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, etc.
  • the bases of suppositories are witepsol, twin (tween) 61, polyethylene glycols, cacao butter, laurin paper, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearate, sorbitan fatty acid esters and the like can be used.
  • Preferred dosages of the pharmaceutical compositions of the present invention range from 0.001 mg / kg to 10 g / kg per day, preferably 0.001 mg / kg to 1 g, depending on the condition, body weight, sex, age, severity of the patient and route of administration. It can range from / kg. Administration can be done once a day or divided into several times. Such dosage should not be construed as limiting the scope of the invention in any aspect.
  • Diphterocappus intricatus extract the active ingredient of the present invention, is similar to arbutin, whose inhibitory activity of tyrosinase is one of the synthetic whitening ingredients, and is significantly higher than that of arbutin in melanin production inhibitory activity.
  • the skin whitening composition of the present invention may be commercialized as food, cosmetics, medicines, etc., and by using a skin whitening material derived from natural products, the side effects may be relatively low compared to the synthetic skin whitening agent.
  • 1 is a result showing the melanin inhibitory activity of diphterocappus intricatus extract in B16F10, a melanoma cell stimulated with ⁇ -MSH, a melanogenesis-stimulating agent.
  • Inhibition% 100- (A-B) / (C-D) x100
  • the inhibitory activity of tyrosinase an enzyme that plays an important role in melanogenesis by measuring the absorbance of melanin, which is oxidized by the substrate L-tyrosine and the enzyme mushroom tyrosinase
  • the sample of Example shows that it has similar tyrosinase inhibitory activity to arbutin, a whitening agent on functional cosmetics.
  • B16 / F10 cells were obtained from Korean Cell Line Bank (KCLB), a mouse melanoma cell line, and 100 units / ml of penicillin-streptomycin (GIBCO, Grand Island, NY, USA) and 10% fetal bovine serum (FBS; Island, NY, USA) was used to incubate in 37 ° C, 5% CO 2 incubator using RPMI 1640 or DMEM medium (GIBCO, Grand Island, NY, USA), subculture every three to four days It was.
  • KCLB Korean Cell Line Bank
  • FBS fetal bovine serum
  • B16F10 melanoma cell line was dispensed into 6 well plates with a cell number of 1 ⁇ 10 5 / well, and after 24 hours, the medium was removed, and 100 nM of ⁇ -melanocyte stimulating hormone ( ⁇ -MSH) and the positive control group arbutin and the sample of Example After treatment, the cells were incubated for 72 hours. After washing twice with PBS, lysis buffer (100 mM sodium phosphate (pH6.8), 0.1 mM PMSF, 1% Triton X-100) was added and dissolved at -80 ° C for 30 minutes. After cell collection, pellets were dissolved by reacting with 1N NaOH containing 10% DMSO at 65 ° C. for 1 hour and absorbance was measured at 405 nm.
  • lysis buffer 100 mM sodium phosphate (pH6.8), 0.1 mM PMSF, 1% Triton X-100
  • the sample of the example shows melanin production inhibitory activity in proportion to the treatment concentration, and melanin production inhibitory activity is clearly superior to arbutin, a positive control group.
  • B16F10 cells were dispensed into 96 well plates at 1 ⁇ 10 4 cells / well, and the samples were treated by concentration (62.5, 125, 250, 500 ⁇ g / ml) and incubated for 24 hours.
  • concentration 62.5, 125, 250, 500 ⁇ g / ml
  • the medium containing 5 mg / ml MTT solution was added and incubated for 2 hours, MTT reagent was removed, DMSO was added, and formazan was dissolved. Thereafter, the absorbance was measured at 540 nm using an ELISA reader.
  • Table 2 shows that the IC 50 of the sample of the example was 500 ⁇ g / ml or more, indicating that the melanogenesis inhibitory activity was not caused by cytotoxicity, and the lowest concentration showing the highest melanogenesis inhibitory activity. Phosphorus 100 ⁇ g / ml shows no cytotoxicity.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition de blanchiment de la peau utilisant un extrait de Dipterocarpus intricatus qui présente une activité élevée d'inhibition de la tyrosinase, et qui présente une activité d'inhibition de la formation de la mélanine dépendant de la concentration lorsqu'elle est utilisée pour traiter la B16F10, qui est une cellule de mélanome stimulée par l'agent α-MSH de stimulation de la formation de la mélanine. L'extrait de Dipterocarpus intricatus présente une activité d'inhibition de la tyrosinase similaire à celle de l'arbutine, qui est une composition de blanchiment synthétique, et en termes d'activité d'inhibition de la formation de la mélanine, est nettement supérieure à celle de l'arbutine, qui est une des compositions de blanchiment synthétique du codex des cosmétiques fonctionnels.
PCT/KR2016/013203 2015-11-16 2016-11-16 Composition de blanchiment de la peau utilisant un extrait de dipterocarpus intricatus WO2017086692A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0160148 2015-11-16
KR1020150160148A KR101742167B1 (ko) 2015-11-16 2015-11-16 디프테로카푸스 인트리카투스 추출물을 이용한 피부 미백용 조성물

Publications (1)

Publication Number Publication Date
WO2017086692A1 true WO2017086692A1 (fr) 2017-05-26

Family

ID=58719032

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/013203 WO2017086692A1 (fr) 2015-11-16 2016-11-16 Composition de blanchiment de la peau utilisant un extrait de dipterocarpus intricatus

Country Status (2)

Country Link
KR (1) KR101742167B1 (fr)
WO (1) WO2017086692A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022171292A1 (fr) 2021-02-12 2022-08-18 Symrise Ag Médicament pour la prévention et le traitement de l'hyperpigmentation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140003727A (ko) * 2012-06-26 2014-01-10 성균관대학교산학협력단 디프테로카르푸스 투베르쿨라투스 추출물을 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 조성물
KR20140048798A (ko) * 2012-10-16 2014-04-24 한국생명공학연구원 딥터로카퍼스 투버큘라투스 추출물 또는 이의 분획물을 함유하는 대사성 질환 예방 및 치료용 약학적 조성물
KR101447007B1 (ko) * 2010-12-27 2014-10-07 한국생명공학연구원 디프테로카퍼스 옵터시포리어스 추출물을 유효성분으로 함유하는 노화방지용 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101447007B1 (ko) * 2010-12-27 2014-10-07 한국생명공학연구원 디프테로카퍼스 옵터시포리어스 추출물을 유효성분으로 함유하는 노화방지용 조성물
KR20140003727A (ko) * 2012-06-26 2014-01-10 성균관대학교산학협력단 디프테로카르푸스 투베르쿨라투스 추출물을 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 조성물
KR20140048798A (ko) * 2012-10-16 2014-04-24 한국생명공학연구원 딥터로카퍼스 투버큘라투스 추출물 또는 이의 분획물을 함유하는 대사성 질환 예방 및 치료용 약학적 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MUHTADI ET AL.: "Resveratrol Tetramer Compounds from Dipterocarpus Intricatus and Activity Againys Murine Leukemia P-388 Cells", PROCEEDING OF THE INTERNATIONAL SEMINAR ON CHEMISTRY, 2008, Indonesia Jatinangor, pages 585, XP055383653, ISBN: 978-979-16962-0-7 *
OHGUCHI, KENJI ET AL.: "Inhibitory Effects of Resveratrol Derivatives from Dipterocarpaceae Plants on Tyrosinase Activity", BIOSCIENCE, BIOTECHNOLOGY AND BIOCHEMISTRY, vol. 67, no. 7, 2003, pages 1587 - 1589, XP007906064 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022171292A1 (fr) 2021-02-12 2022-08-18 Symrise Ag Médicament pour la prévention et le traitement de l'hyperpigmentation

Also Published As

Publication number Publication date
KR20170056835A (ko) 2017-05-24
KR101742167B1 (ko) 2017-05-31

Similar Documents

Publication Publication Date Title
WO2023113111A1 (fr) Composition de blanchiment de la peau pour soulager le mélasme, les taches de vieillesse, etc. à l'aide d'une gomme mastic soluble dans l'eau
KR102128977B1 (ko) 흰꽃여뀌 추출물을 이용한 피부 주름 개선 및 피부 미백용 조성물
WO2017086692A1 (fr) Composition de blanchiment de la peau utilisant un extrait de dipterocarpus intricatus
KR102301299B1 (ko) 큰도꼬마리 추출물을 이용한 피부 미백용 조성물
KR102333208B1 (ko) 율무 미강 추출물 또는 그 발효물을 이용한 피부 미백용 조성물
KR20230033388A (ko) 푸른여로 추출물을 이용한 피부 주름 개선 및 피부 미백용 조성물
KR101568656B1 (ko) 산유자 추출물을 이용한 피부 미백용 조성물
KR101742162B1 (ko) 디프테로카푸스 인트리카투스 추출물을 이용한 피부 미백용 식품 조성물
KR102468186B1 (ko) 벌노랑이 추출물을 이용한 피부 미백용 조성물
KR102378489B1 (ko) 이삭여뀌 추출물 또는 이로부터 분리된 화합물을 이용한 피부 미백용 조성물
KR102510149B1 (ko) 바위수국 추출물을 이용한 피부 미백용 조성물
KR102048973B1 (ko) 진세노사이드 화합물 k와 쌀겨 추출물을 이용한 피부 미백용 조성물
KR102218472B1 (ko) 개싱아 추출물을 이용한 피부 미백용 조성물
KR102229943B1 (ko) 마에루아 에둘리스 추출물을 이용한 피부 미백용 조성물
KR102289102B1 (ko) 박새 추출물을 이용한 피부 미백 및 주름 개선용 조성물
KR102374474B1 (ko) 꿩의다리아재비 추출물을 이용한 피부 미백용 조성물
WO2023167367A1 (fr) Composition d'éclaircissement de la peau et de réduction des rides cutanées à l'aide de curcumine soluble dans l'eau et d'un extrait de son de blé
KR102606796B1 (ko) 콩배나무 추출물을 이용한 피부 주름 개선 및 피부 미백용 조성물
KR102374364B1 (ko) 물꼬챙이골 추출물을 이용한 피부 미백용 조성물
KR102625163B1 (ko) 물박달나무 추출물을 이용한 피부 주름 개선 및 피부 미백용 조성물
KR102615923B1 (ko) 잔사틴을 이용한 피부 미백용 조성물
KR102045293B1 (ko) 쉰다리 및 참꽃나무 꽃잎 혼합추출물을 이용한 피부 미백용 조성물
WO2024128333A1 (fr) Composition utilisant un extrait veratrum versicolor pour atténuer les rides de la peau et blanchir la peau
KR101867350B1 (ko) 산양삼 종자 효소 처리 추출물을 이용한 피부 미백용 조성물
KR20230073772A (ko) 인진쑥 추출물과 유자 추출물의 혼합물을 이용한 피부 미백과 피부 주름 개선용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16866644

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16866644

Country of ref document: EP

Kind code of ref document: A1